Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 57 | 2024 | 5670 | 3.680 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 11 | 2023 | 269 | 3.640 |
Why?
|
Graft vs Host Disease | 41 | 2024 | 3030 | 3.410 |
Why?
|
Immunotherapy, Adoptive | 19 | 2024 | 1469 | 2.030 |
Why?
|
Transplantation, Homologous | 23 | 2024 | 4808 | 1.480 |
Why?
|
Transplantation Conditioning | 18 | 2024 | 1590 | 1.330 |
Why?
|
Hematologic Neoplasms | 16 | 2024 | 1896 | 1.120 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2019 | 305 | 1.110 |
Why?
|
Epstein-Barr Virus Infections | 6 | 2024 | 612 | 1.060 |
Why?
|
Lymphoproliferative Disorders | 3 | 2024 | 533 | 1.020 |
Why?
|
Herpesvirus 4, Human | 9 | 2024 | 1079 | 0.920 |
Why?
|
Myelodysplastic Syndromes | 6 | 2024 | 1394 | 0.860 |
Why?
|
Antigens, CD34 | 3 | 2024 | 658 | 0.850 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 2 | 2018 | 95 | 0.760 |
Why?
|
T-Lymphocytes | 15 | 2024 | 10194 | 0.720 |
Why?
|
Leukemia, Myeloid, Acute | 10 | 2024 | 3613 | 0.720 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2022 | 306 | 0.670 |
Why?
|
Treatment Failure | 3 | 2024 | 2642 | 0.660 |
Why?
|
Interleukin-2 | 8 | 2022 | 1891 | 0.650 |
Why?
|
Myeloablative Agonists | 4 | 2018 | 209 | 0.650 |
Why?
|
Macrophage Activation Syndrome | 1 | 2019 | 124 | 0.630 |
Why?
|
Graft vs Tumor Effect | 1 | 2016 | 68 | 0.530 |
Why?
|
Transplants | 1 | 2018 | 206 | 0.530 |
Why?
|
Graft vs Leukemia Effect | 2 | 2020 | 121 | 0.510 |
Why?
|
Fetal Blood | 3 | 2016 | 1347 | 0.500 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 238 | 0.500 |
Why?
|
Lymphocyte Transfusion | 1 | 2016 | 232 | 0.500 |
Why?
|
Neurotoxicity Syndromes | 4 | 2023 | 300 | 0.490 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2018 | 557 | 0.480 |
Why?
|
Hepatic Veno-Occlusive Disease | 3 | 2022 | 220 | 0.450 |
Why?
|
Receptors, Antigen, T-Cell | 8 | 2024 | 2549 | 0.450 |
Why?
|
T-Lymphocytes, Regulatory | 9 | 2022 | 3077 | 0.440 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 686 | 0.440 |
Why?
|
Antilymphocyte Serum | 1 | 2015 | 487 | 0.440 |
Why?
|
Hematopoietic Stem Cells | 5 | 2022 | 3396 | 0.410 |
Why?
|
Viral Matrix Proteins | 1 | 2014 | 196 | 0.410 |
Why?
|
Lymphoma | 4 | 2020 | 1901 | 0.410 |
Why?
|
Cytokines | 6 | 2024 | 7392 | 0.400 |
Why?
|
Recurrence | 16 | 2024 | 8469 | 0.390 |
Why?
|
Antigens, CD19 | 4 | 2022 | 425 | 0.370 |
Why?
|
Tissue Donors | 5 | 2022 | 2331 | 0.360 |
Why?
|
Gastrointestinal Diseases | 1 | 2018 | 1199 | 0.340 |
Why?
|
Humans | 118 | 2024 | 761423 | 0.340 |
Why?
|
Organ Transplantation | 3 | 2024 | 1157 | 0.340 |
Why?
|
Pyrazoles | 2 | 2019 | 2007 | 0.330 |
Why?
|
Adult | 61 | 2024 | 221148 | 0.330 |
Why?
|
Blood Component Removal | 2 | 2022 | 132 | 0.330 |
Why?
|
Virus Diseases | 1 | 2015 | 719 | 0.320 |
Why?
|
Antiphospholipid Syndrome | 1 | 2010 | 165 | 0.300 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 3 | 2003 | 157 | 0.300 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2020 | 1374 | 0.300 |
Why?
|
Ferritins | 3 | 2022 | 597 | 0.290 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2022 | 1405 | 0.280 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2020 | 4370 | 0.280 |
Why?
|
B-Lymphocytes | 5 | 2024 | 4764 | 0.280 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2014 | 1784 | 0.270 |
Why?
|
Steroids | 6 | 2023 | 929 | 0.270 |
Why?
|
Aged | 42 | 2024 | 169235 | 0.260 |
Why?
|
Middle Aged | 48 | 2024 | 220826 | 0.250 |
Why?
|
Multiple Myeloma | 2 | 2023 | 5146 | 0.240 |
Why?
|
Cyclophosphamide | 6 | 2023 | 2218 | 0.240 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2021 | 1640 | 0.230 |
Why?
|
Killer Cells, Natural | 6 | 2022 | 2203 | 0.230 |
Why?
|
CD8-Positive T-Lymphocytes | 9 | 2024 | 4575 | 0.230 |
Why?
|
Dioxygenases | 3 | 2021 | 345 | 0.230 |
Why?
|
Transplantation Chimera | 3 | 2015 | 594 | 0.230 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2022 | 225 | 0.220 |
Why?
|
Male | 50 | 2024 | 360736 | 0.220 |
Why?
|
Young Adult | 20 | 2024 | 59207 | 0.210 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 21 | 0.210 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2003 | 1351 | 0.210 |
Why?
|
Perforin | 2 | 2018 | 167 | 0.210 |
Why?
|
Female | 50 | 2024 | 392581 | 0.200 |
Why?
|
Transplantation, Autologous | 4 | 2021 | 2116 | 0.200 |
Why?
|
Ligands | 2 | 2018 | 3271 | 0.190 |
Why?
|
Autoantibodies | 1 | 2010 | 2124 | 0.190 |
Why?
|
Anemia, Sickle Cell | 2 | 2020 | 1064 | 0.190 |
Why?
|
Opportunistic Infections | 1 | 2023 | 376 | 0.180 |
Why?
|
Clone Cells | 4 | 2020 | 1659 | 0.180 |
Why?
|
Natural Killer T-Cells | 1 | 2024 | 322 | 0.180 |
Why?
|
Survival Rate | 9 | 2022 | 12720 | 0.170 |
Why?
|
gamma-Globins | 1 | 2020 | 106 | 0.170 |
Why?
|
Janus Kinase 1 | 1 | 2019 | 107 | 0.170 |
Why?
|
Certification | 1 | 2023 | 418 | 0.160 |
Why?
|
BK Virus | 1 | 2020 | 123 | 0.160 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 225 | 0.160 |
Why?
|
Photopheresis | 1 | 2019 | 35 | 0.160 |
Why?
|
Disease-Free Survival | 6 | 2018 | 6814 | 0.160 |
Why?
|
Bone Marrow Transplantation | 2 | 2023 | 2695 | 0.160 |
Why?
|
Retrospective Studies | 21 | 2024 | 80582 | 0.150 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2019 | 299 | 0.150 |
Why?
|
Biological Products | 3 | 2022 | 912 | 0.150 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2018 | 263 | 0.150 |
Why?
|
Fetal Hemoglobin | 1 | 2020 | 345 | 0.150 |
Why?
|
Lymphocyte Activation | 4 | 2022 | 5490 | 0.150 |
Why?
|
Chronic Disease | 11 | 2023 | 9320 | 0.150 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2021 | 651 | 0.150 |
Why?
|
Vidarabine | 4 | 2021 | 336 | 0.150 |
Why?
|
Heterocyclic Compounds | 1 | 2018 | 246 | 0.140 |
Why?
|
Cytomegalovirus Infections | 1 | 2023 | 831 | 0.140 |
Why?
|
Sulfonamides | 2 | 2024 | 1975 | 0.140 |
Why?
|
Treatment Outcome | 12 | 2024 | 64651 | 0.140 |
Why?
|
Hematologic Diseases | 2 | 2018 | 496 | 0.130 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 8000 | 0.130 |
Why?
|
Janus Kinase 2 | 1 | 2019 | 560 | 0.130 |
Why?
|
Tacrolimus | 4 | 2023 | 733 | 0.130 |
Why?
|
Cryopreservation | 2 | 2021 | 728 | 0.130 |
Why?
|
Down-Regulation | 2 | 2020 | 2918 | 0.130 |
Why?
|
Tandem Repeat Sequences | 1 | 2016 | 180 | 0.130 |
Why?
|
Stem Cell Factor | 1 | 2015 | 195 | 0.120 |
Why?
|
Interleukin-7 | 1 | 2015 | 142 | 0.120 |
Why?
|
Mediastinal Neoplasms | 1 | 2017 | 401 | 0.120 |
Why?
|
Kidney | 2 | 2010 | 7049 | 0.120 |
Why?
|
Cell Division | 2 | 2004 | 4466 | 0.120 |
Why?
|
T-Lymphocyte Subsets | 3 | 2016 | 1806 | 0.120 |
Why?
|
Lymphocyte Depletion | 1 | 2016 | 602 | 0.120 |
Why?
|
Nitriles | 1 | 2019 | 971 | 0.120 |
Why?
|
Niacinamide | 1 | 2016 | 413 | 0.110 |
Why?
|
Brain Edema | 1 | 2018 | 604 | 0.110 |
Why?
|
HLA Antigens | 1 | 2019 | 1371 | 0.110 |
Why?
|
Busulfan | 3 | 2021 | 258 | 0.110 |
Why?
|
Combined Modality Therapy | 3 | 2024 | 8529 | 0.110 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 2024 | 1469 | 0.110 |
Why?
|
Antigens, Surface | 1 | 2017 | 1609 | 0.110 |
Why?
|
Receptors, Interleukin-2 | 1 | 2015 | 562 | 0.110 |
Why?
|
Adolescent | 13 | 2024 | 88313 | 0.110 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 529 | 0.110 |
Why?
|
Remission Induction | 2 | 2016 | 2395 | 0.110 |
Why?
|
Consensus | 1 | 2023 | 3122 | 0.110 |
Why?
|
Drug Resistance | 1 | 2019 | 1595 | 0.110 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2016 | 495 | 0.100 |
Why?
|
Lymphocyte Count | 3 | 2019 | 778 | 0.100 |
Why?
|
DNA-Binding Proteins | 4 | 2021 | 9606 | 0.100 |
Why?
|
Histocompatibility Testing | 3 | 2015 | 719 | 0.100 |
Why?
|
Models, Immunological | 1 | 2014 | 513 | 0.100 |
Why?
|
Repressor Proteins | 2 | 2020 | 2985 | 0.100 |
Why?
|
Child | 8 | 2023 | 80162 | 0.100 |
Why?
|
RNA Interference | 1 | 2020 | 2831 | 0.100 |
Why?
|
Incidence | 4 | 2023 | 21341 | 0.100 |
Why?
|
Gene Deletion | 1 | 2019 | 2667 | 0.100 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 1551 | 0.100 |
Why?
|
Neoplasm, Residual | 1 | 2016 | 1008 | 0.090 |
Why?
|
Mutation | 6 | 2021 | 30045 | 0.090 |
Why?
|
Saccharomyces cerevisiae | 1 | 2022 | 2687 | 0.090 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 1745 | 0.090 |
Why?
|
Cell Separation | 1 | 2016 | 1721 | 0.090 |
Why?
|
Lymphoma, B-Cell | 1 | 2017 | 940 | 0.090 |
Why?
|
Cell Proliferation | 4 | 2019 | 10441 | 0.090 |
Why?
|
Receptors, IgE | 2 | 2003 | 374 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1924 | 0.090 |
Why?
|
Prognosis | 6 | 2022 | 29620 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 617 | 0.090 |
Why?
|
Cytomegalovirus | 1 | 2015 | 756 | 0.090 |
Why?
|
Stilbenes | 1 | 2011 | 155 | 0.090 |
Why?
|
Phagocytosis | 2 | 2015 | 1536 | 0.090 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2016 | 974 | 0.090 |
Why?
|
Herpesvirus 8, Human | 2 | 2004 | 255 | 0.090 |
Why?
|
Boronic Acids | 1 | 2014 | 915 | 0.090 |
Why?
|
Hematopoiesis | 2 | 2017 | 2049 | 0.080 |
Why?
|
Neoplasms | 3 | 2024 | 22164 | 0.080 |
Why?
|
Alleles | 4 | 2024 | 6922 | 0.080 |
Why?
|
Prednisone | 1 | 2014 | 1562 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2011 | 4354 | 0.080 |
Why?
|
Plasmapheresis | 1 | 2010 | 206 | 0.080 |
Why?
|
United States | 8 | 2024 | 72339 | 0.080 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 1600 | 0.080 |
Why?
|
Hodgkin Disease | 1 | 2017 | 1378 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3612 | 0.080 |
Why?
|
Leukocytes, Mononuclear | 1 | 2016 | 1843 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1051 | 0.080 |
Why?
|
Glioblastoma | 1 | 2024 | 3482 | 0.080 |
Why?
|
Phenotype | 2 | 2018 | 16606 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1964 | 0.080 |
Why?
|
Epitopes | 1 | 2015 | 2507 | 0.080 |
Why?
|
Cells, Cultured | 4 | 2016 | 18964 | 0.080 |
Why?
|
Pyrazines | 1 | 2014 | 1201 | 0.080 |
Why?
|
Whole-Body Irradiation | 2 | 2019 | 433 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2811 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 15941 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5665 | 0.070 |
Why?
|
Erythropoiesis | 1 | 2011 | 682 | 0.070 |
Why?
|
Erythrocytes | 1 | 2016 | 2419 | 0.070 |
Why?
|
Pyrimidines | 1 | 2019 | 3027 | 0.070 |
Why?
|
Survival Analysis | 5 | 2018 | 10089 | 0.070 |
Why?
|
Age Factors | 3 | 2024 | 18400 | 0.070 |
Why?
|
Immunotherapy | 2 | 2019 | 4650 | 0.070 |
Why?
|
Fas Ligand Protein | 2 | 2003 | 216 | 0.070 |
Why?
|
Cell Line, Tumor | 4 | 2018 | 16979 | 0.070 |
Why?
|
Lymphocytes | 2 | 2024 | 2611 | 0.060 |
Why?
|
Melanoma | 1 | 2024 | 5709 | 0.060 |
Why?
|
Neutropenia | 1 | 2010 | 884 | 0.060 |
Why?
|
Antigens, CD7 | 1 | 2024 | 30 | 0.060 |
Why?
|
Disease Management | 1 | 2015 | 2507 | 0.060 |
Why?
|
Polyglutamic Acid | 2 | 1994 | 47 | 0.060 |
Why?
|
Trans-Activators | 2 | 2007 | 2856 | 0.060 |
Why?
|
Neutrophils | 1 | 2016 | 3766 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 1624 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2017 | 1866 | 0.060 |
Why?
|
Pore Forming Cytotoxic Proteins | 1 | 2003 | 133 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2020 | 58956 | 0.050 |
Why?
|
Immunoglobulin A | 1 | 2007 | 980 | 0.050 |
Why?
|
Societies | 1 | 2023 | 108 | 0.050 |
Why?
|
Antigens, CD | 2 | 2024 | 4001 | 0.050 |
Why?
|
RNA, Transfer, Lys | 1 | 2002 | 8 | 0.050 |
Why?
|
NF-kappa B | 1 | 2011 | 2488 | 0.050 |
Why?
|
Antigens, Viral | 1 | 2007 | 988 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3082 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 98 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3202 | 0.050 |
Why?
|
Immunophenotyping | 2 | 2018 | 1870 | 0.050 |
Why?
|
Cell Transformation, Viral | 1 | 2003 | 526 | 0.050 |
Why?
|
Azacitidine | 1 | 2024 | 336 | 0.050 |
Why?
|
Immunologic Memory | 2 | 2016 | 1358 | 0.050 |
Why?
|
Serology | 1 | 2001 | 7 | 0.050 |
Why?
|
HIV Reverse Transcriptase | 1 | 2002 | 212 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2273 | 0.050 |
Why?
|
Graft Rejection | 1 | 2014 | 4445 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 263 | 0.050 |
Why?
|
Anemia | 1 | 2010 | 1508 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 136 | 0.050 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2022 | 899 | 0.040 |
Why?
|
Immunomodulation | 1 | 2024 | 548 | 0.040 |
Why?
|
Intubation | 1 | 2020 | 139 | 0.040 |
Why?
|
Respiratory Therapy | 1 | 2020 | 125 | 0.040 |
Why?
|
Burkitt Lymphoma | 1 | 2002 | 335 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6479 | 0.040 |
Why?
|
Signal Transduction | 3 | 2019 | 23441 | 0.040 |
Why?
|
Methotrexate | 2 | 2018 | 1718 | 0.040 |
Why?
|
Viral Proteins | 1 | 2007 | 1803 | 0.040 |
Why?
|
Toll-Like Receptor 9 | 1 | 2020 | 233 | 0.040 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2003 | 1444 | 0.040 |
Why?
|
Cell Size | 1 | 2001 | 624 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 891 | 0.040 |
Why?
|
Leukemia, Myeloid | 1 | 2021 | 694 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 1090 | 0.040 |
Why?
|
Amino Acid Substitution | 2 | 2018 | 1738 | 0.040 |
Why?
|
Biopsy | 1 | 2010 | 6766 | 0.040 |
Why?
|
Melphalan | 1 | 2019 | 420 | 0.040 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2000 | 439 | 0.040 |
Why?
|
Risk Factors | 4 | 2020 | 74167 | 0.040 |
Why?
|
Mice, Mutant Strains | 1 | 2020 | 1750 | 0.040 |
Why?
|
Benzylamines | 1 | 2018 | 247 | 0.040 |
Why?
|
Acute Disease | 2 | 2020 | 7238 | 0.040 |
Why?
|
Immediate-Early Proteins | 1 | 2000 | 449 | 0.040 |
Why?
|
Th1 Cells | 1 | 2002 | 1037 | 0.040 |
Why?
|
Cell Line | 4 | 2004 | 15605 | 0.040 |
Why?
|
Coculture Techniques | 2 | 2016 | 1340 | 0.040 |
Why?
|
Simian immunodeficiency virus | 1 | 2002 | 809 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 883 | 0.030 |
Why?
|
Time Factors | 4 | 2021 | 39975 | 0.030 |
Why?
|
Leukopenia | 1 | 2017 | 213 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2024 | 1994 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 2 | 2020 | 4510 | 0.030 |
Why?
|
Lymphocyte Cooperation | 1 | 2016 | 113 | 0.030 |
Why?
|
Pilot Projects | 2 | 2020 | 8633 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2016 | 13637 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2020 | 1612 | 0.030 |
Why?
|
Germ Cells | 1 | 2020 | 634 | 0.030 |
Why?
|
STAT5 Transcription Factor | 1 | 2016 | 264 | 0.030 |
Why?
|
Workflow | 1 | 2021 | 851 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2022 | 39117 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 4741 | 0.030 |
Why?
|
Membrane Glycoproteins | 2 | 2003 | 3702 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2024 | 1664 | 0.030 |
Why?
|
Outpatients | 1 | 2023 | 1597 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9277 | 0.030 |
Why?
|
Antibodies, Viral | 1 | 2007 | 3155 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2015 | 17912 | 0.030 |
Why?
|
Animals | 5 | 2024 | 168441 | 0.030 |
Why?
|
Lymphopoiesis | 1 | 2016 | 133 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2017 | 878 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2007 | 5868 | 0.030 |
Why?
|
Graft Survival | 2 | 2017 | 3819 | 0.030 |
Why?
|
Inflammation | 1 | 2015 | 10762 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 14026 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2020 | 832 | 0.030 |
Why?
|
Platelet Count | 1 | 2017 | 782 | 0.030 |
Why?
|
Anticoagulants | 1 | 2010 | 4813 | 0.030 |
Why?
|
Virus Replication | 1 | 2002 | 2435 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2024 | 1808 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2004 | 3207 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2018 | 1834 | 0.030 |
Why?
|
Chemoembolization, Therapeutic | 1 | 1994 | 128 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3304 | 0.030 |
Why?
|
Leukemia | 1 | 2021 | 1522 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2016 | 859 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10766 | 0.030 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2016 | 629 | 0.030 |
Why?
|
Antibody Formation | 1 | 2017 | 1398 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 5302 | 0.030 |
Why?
|
Dendritic Cells | 1 | 2003 | 2746 | 0.030 |
Why?
|
Plasma Cells | 1 | 2016 | 599 | 0.030 |
Why?
|
RNA | 1 | 2002 | 2723 | 0.020 |
Why?
|
Syndrome | 1 | 2018 | 3268 | 0.020 |
Why?
|
Death | 1 | 2016 | 676 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2824 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2024 | 9535 | 0.020 |
Why?
|
Cell Count | 1 | 2016 | 1835 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1793 | 0.020 |
Why?
|
Disease Progression | 2 | 2020 | 13502 | 0.020 |
Why?
|
Erythroid-Specific DNA-Binding Factors | 1 | 2011 | 195 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2020 | 3428 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1876 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2018 | 21012 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2020 | 3395 | 0.020 |
Why?
|
Pandemics | 2 | 2021 | 8641 | 0.020 |
Why?
|
Genetic Markers | 1 | 2017 | 2613 | 0.020 |
Why?
|
Skin Diseases | 1 | 2019 | 1093 | 0.020 |
Why?
|
Erythroid Precursor Cells | 1 | 2011 | 211 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2192 | 0.020 |
Why?
|
Immune Tolerance | 1 | 2019 | 2300 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3381 | 0.020 |
Why?
|
Antibodies | 1 | 2017 | 2421 | 0.020 |
Why?
|
Th17 Cells | 1 | 2016 | 794 | 0.020 |
Why?
|
Lung Diseases | 1 | 2019 | 1909 | 0.020 |
Why?
|
Kidney Transplantation | 1 | 2024 | 4234 | 0.020 |
Why?
|
Cisplatin | 1 | 1994 | 1650 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3823 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4110 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4244 | 0.020 |
Why?
|
Prospective Studies | 3 | 2020 | 54415 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9330 | 0.020 |
Why?
|
Kinetics | 1 | 2015 | 6374 | 0.020 |
Why?
|
Cohort Studies | 3 | 2018 | 41446 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2016 | 2908 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2011 | 13337 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5441 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12330 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2916 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2011 | 1334 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2024 | 22163 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9179 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4172 | 0.020 |
Why?
|
Mice | 2 | 2024 | 81509 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2024 | 18247 | 0.020 |
Why?
|
HIV-1 | 1 | 2002 | 6860 | 0.010 |
Why?
|
Contactins | 1 | 2004 | 21 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2371 | 0.010 |
Why?
|
Genetic Variation | 1 | 2019 | 6581 | 0.010 |
Why?
|
Neural Cell Adhesion Molecules | 1 | 2004 | 122 | 0.010 |
Why?
|
Binding Sites | 2 | 2002 | 6055 | 0.010 |
Why?
|
Child, Preschool | 2 | 2021 | 42254 | 0.010 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2011 | 1606 | 0.010 |
Why?
|
Gene Expression | 1 | 2016 | 7584 | 0.010 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 2002 | 151 | 0.010 |
Why?
|
HLA-DQ Antigens | 1 | 2002 | 211 | 0.010 |
Why?
|
Viral Core Proteins | 1 | 2002 | 161 | 0.010 |
Why?
|
Base Sequence | 2 | 2003 | 12450 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12058 | 0.010 |
Why?
|
Gene Products, gag | 1 | 2002 | 312 | 0.010 |
Why?
|
Models, Molecular | 1 | 2011 | 5439 | 0.010 |
Why?
|
Glycosylation | 1 | 2004 | 1098 | 0.010 |
Why?
|
Phosphonoacetic Acid | 1 | 2000 | 54 | 0.010 |
Why?
|
Contrast Media | 1 | 1994 | 5311 | 0.010 |
Why?
|
HLA-DR Antigens | 1 | 2002 | 631 | 0.010 |
Why?
|
Particle Size | 2 | 1994 | 1646 | 0.010 |
Why?
|
Nucleotides | 1 | 2002 | 454 | 0.010 |
Why?
|
Infant | 1 | 2021 | 36205 | 0.010 |
Why?
|
Pyridines | 1 | 2011 | 2875 | 0.010 |
Why?
|
DNA Primers | 1 | 2003 | 2820 | 0.010 |
Why?
|
Deoxyribonucleases | 1 | 2000 | 211 | 0.010 |
Why?
|
Plasmids | 1 | 2004 | 2269 | 0.010 |
Why?
|
Nucleic Acid Conformation | 1 | 2002 | 902 | 0.010 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2002 | 825 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2004 | 4174 | 0.010 |
Why?
|
Recombination, Genetic | 1 | 2002 | 1525 | 0.010 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2000 | 621 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11740 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2011 | 5305 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 23990 | 0.010 |
Why?
|
Iopanoic Acid | 1 | 1994 | 20 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2004 | 6532 | 0.010 |
Why?
|
Capsules | 1 | 1994 | 191 | 0.010 |
Why?
|
DNA, Viral | 1 | 2000 | 2201 | 0.010 |
Why?
|
Estrone | 1 | 1994 | 234 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2000 | 6132 | 0.010 |
Why?
|
Enzymes | 1 | 1994 | 258 | 0.010 |
Why?
|
Escherichia coli | 1 | 2004 | 4218 | 0.010 |
Why?
|
Microspheres | 1 | 1994 | 785 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2004 | 5115 | 0.010 |
Why?
|
Tissue Distribution | 1 | 1994 | 2265 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2002 | 17644 | 0.010 |
Why?
|
Drug Carriers | 1 | 1994 | 706 | 0.010 |
Why?
|
Rabbits | 1 | 1994 | 4779 | 0.000 |
Why?
|
Receptors, Estrogen | 1 | 1994 | 2208 | 0.000 |
Why?
|
RNA, Messenger | 1 | 2000 | 12796 | 0.000 |
Why?
|
Swine | 1 | 1994 | 5914 | 0.000 |
Why?
|
Liver | 1 | 1994 | 7532 | 0.000 |
Why?
|
Rats | 1 | 1994 | 23742 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 1994 | 20556 | 0.000 |
Why?
|